The Promus Diagnostics’ CFR panel is a real-time RT-PCR test designed for the qualitative detection of RNA from the SARS-CoV-2, Influenza A/B (Flu A/B), and Human Respiratory Syncytial Virus A/B (RSV A/B) in respiratory specimens (nasopharyngeal swab and oropharyngeal swab) from individuals suspected of respiratory infections by their healthcare provider.
The CFR panel detects the presence of Influenza and RSV, but does not differentiate between types A or B. In one convenient test, healthcare providers can quickly diagnose the underlying cause of a respiratory infection, relying on the accuracy of RT-PCR technology that examines the presence of SARS-CoV-2, Flu, and RSV at the RNA level of the virus.
CFR is a Laboratory Developed Test (LDT) using Real-Time PCR amplification of defined targets. This test has not been cleared or approved by the FDA, however, approval/clearance is not required as Promus Diagnostics LLC is certified under CLIA to perform high-complexity clinical laboratory testing. CFR is used for clinical purposes and should not be regarded as investigational or for research.